Demographic and epidemiologic transition in the developing world: Role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease  by Correa-Rotter, Ricardo et al.
Kidney International, Vol. 66, Supplement 92 (2004), pp. S32–S37
Demographic and epidemiologic transition in the developing
world: Role of albuminuria in the early diagnosis and prevention
of renal and cardiovascular disease
RICARDO CORREA-ROTTER, SARALA NAICKER, IVOR J. KATZ, SANJAY K. AGARWAL,
RAUL HERRERA VALDES, DAN KASEJE, BERNARDO RODRIGUEZ-ITURBE, FAISSAL SHAHEEN,
and CHITR SITTHI-AMORN, ON BEHALF OF THE ISN-COMGAN BELLAGIO STUDY GROUP 2004
Instituto Nacional de Ciencias Me´dicas y Nutricio´n Salvador Zubira´n, Mexico City, Mexico; Johannesburg Hospital, Johannesburg,
South Africa; Chris Hani Baragwanath Nephrology Unit, Norwood, South Africa; AIIMS, New Delhi, India; Instituto de
Nefrologia, Havana, Cuba; Tropical Institute of Community Health and Development in Africa (TICH), Kisumu, Kenya; Hospital
Universitario Universidad Del Zulia, Maracaibo, Venezuela; Saudi Center for Organ Transplantation, Jedda, Saudi Arabia; and
Institute of Health Research, Chulalongkorn University, Bangkok, Thailand
Demographic and epidemiologic transition in the developing
world: Role of albuminuria in the early diagnosis and preven-
tion of renal and cardiovascular disease. The developing world
is facing a real pandemic of renal and cardiovascular disease.
With the decrease of infectious disease morbidity and mortal-
ity, and the exposure to more westernized life style, signs of in-
creasing renal and cardiovascular disease is particularly shown
in the tremendous rise in type 2 diabetes and its sequelae. A
group of doctors and scientists from all over the world have
convened in Bellagio to halt this dramatic disease change and
burden to the developing countries. They came to the conclu-
sion that screening and treatment should clearly focus on cost-
beneficial strategies, among which blood pressure and urinary
albumin measurement, as well as effective and affordable treat-
ment strategies to lower blood pressure and albuminuria, are
essential.
Disease burden change in the developing world
During the last 50 years the world has experienced
significant demographic changes, and particularly promi-
nent are those observed in the developing nations. There
has been an almost universal decline in fertility and birth
rate, and a major increase in life expectancy with a con-
sequent increase in age of populations; this again has
been more pronounced in the developing world [1, 2].
A longer life expectancy has been the result of a combi-
nation of several factors, including advances in medical
practice and technology in particular related to communi-
cable and perinatal diseases, reduction of nutritional defi-
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ciency disorders, urbanization, education initiatives, eco-
nomic improvement, the development of public health
programs, and implementation of sanitation practices [3].
Coupled with this demographic transition is an epi-
demiologic transition characterized by an increase in the
incidence and prevalence of chronic noncommunicable
diseases, with the burden of disease changing from the
younger individuals toward the adult population, partic-
ularly the elderly, and bearing a disease has shifted from
being a short process to becoming part of our daily exis-
tence [1, 2, 4, 5].
A second phenomenon that has emerged is the explo-
sive migratory movement of individuals from the coun-
tryside toward the cities, which has determined that the
population living in urban areas has increased enor-
mously. Between 1950 and 2000, the urban population
of the developing nations has increased more than five
times. This massive urban growth has augmented the
presence of irregular settlements lacking those services
and facilities required for health care. Coincident with
the shift in population from rural to urban areas, smoking,
high-fat diets, and other adverse lifestyle factors, which
run parallel to development and industrialization, have
dramatically increased. This phenomenon has been fur-
ther favored by advertising and promotion of entities that
view these regions of the planet as attractive, unregulated,
and uneducated markets with a high potential for selling
and consuming unhealthy products, such as tobacco and
high carbohydrate or fat foods, products that are losing
consumers and advocates in the highly developed coun-
tries. This additional factor has negatively impacted the
already alarming rates of growth of pathologic conditions
such as diabetes mellitus, obesity, chronic kidney diseases,
cardiovascular diseases, and cancer, and have increased
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them even more than would be predicted in relation to
an aging population [6–10].
This epidemiologic and demographic transition is not
homogeneous in the diversity of emerging nations, and
while it is happening at an enormous rate in countries
like China, India, and most of Southeast Asia, as well as
Latin America, other regions of the world are still strug-
gling with devastating epidemics of communicable dis-
eases. This is particularly true for most of sub-Saharan
Africa, which faces the HIV/AIDS epidemic. Neverthe-
less, even in this region and others still struggling with
infectious diseases as tuberculosis, AIDS, and viral hep-
atitis, growing urban concentrations are also dealing with
an increase in chronic conditions that were not present
decades before, and an increasing contribution of these
noncommunicable diseases is common and consistent to
almost all of them [2–4].
Consequences of change in disease patterns
The social, economic, and public health consequences
of the expected increase in the burden of chronic noncom-
municable diseases may be of devastating consequences
for emerging countries. Disability and death of individu-
als in the productive years of life, lack of health care fa-
cilities needed to provide adequate management, costly
burden of interventions and drugs required to treat en-
tities such as diabetes mellitus, end-stage renal disease,
coronary disease, or other, may not be available or af-
fordable in most instances. Nations that are required to
invest their scarce resources in development programs
may be unable to cope with the costs of medical care
requiring technology intensive treatments, as is the case
with most established chronic diseases.
Of particular relevance among the chronic noncom-
municable diseases and major contributors to the excess
morbidity and mortality attributed to this epidemiologic
transition are those that share as a common denomina-
tor the presence of vascular injury and cardiovascular
death. This group of diseases encompasses entities as dia-
betes mellitus and its chronic complications, in particular
diabetic nephropathy, essential hypertension, coronary
heart disease, and other chronic renal diseases [2, 11, 12].
Growth in type 2 diabetes
Non–insulin-dependent or type 2 diabetes mellitus is
one of the most alarming health problems that we will
have to deal with during the first half of this 21st century,
and it may well be the largest public health challenge for
this period. While the prevalence of type 2 diabetes for
the year 2000 was around 188 million patients, it is es-
timated that by the year 2030 there will be more than
400 million individuals suffering this disease (97% will
have type 2 diabetes mellitus) [12]. Increased prevalence
of type 2 diabetes mellitus is expected to occur world-
wide; nevertheless, developed nations (the USA or those
of the European Union) are expecting an increase of be-
tween 40% and 70% in the next 30 years, while that in
developing areas of the world (China, India, Latin Amer-
ica, Southeast Asia, Middle Eastern countries, and sub-
Saharan Africa) will be around 250% in the same period.
In addition, the increase in life expectancy present in all
societies will anticipate a constant increase in the inci-
dence and prevalence of chronic complications such as
diabetic nephropathy.
Diabetes mellitus and its associated complications have
acquired pandemic proportions. It is important to remem-
ber that the mortality of diabetic patients is largely related
to cardiovascular complications that require costly medi-
cal procedures, which may impose an even larger financial
burden to the system [13]. In addition, given the present
medical and technologic advances, there may be a sig-
nificant increase in survival with chronic complications,
which can become economically unmanageable for many
nations. Historically, in developed nations the cardiovas-
cular disease epidemic is usually initiated in the high so-
cial strata as this group changes to a high-risk lifestyle
accompanied by high carbohydrate and fat meals, physi-
cal inactivity, and tobacco consumption. The risk later on
is transmitted to all social groups and classes. The higher-
social classes are again the first to respond to the knowl-
edge of risk factors and the message of prevention and
a subsequent decline of cardiovascular complications or
disease. In the developing world it has been suggested
that the usual pattern is replicated, with cardiovascular
diseases being more common in the wealthier and more
educated strata, and the burden of disease shifting pro-
gressively to the lower social classes. Nevertheless, studies
coming from the Caribbean and Latin American nations
show that poor individuals are more likely to be obese
or to have chronic complications of diabetes mellitus [8].
In a similar fashion, it was reported in India that belong-
ing to a lower socioeconomical strata may be associated
with an increased risk for development of cardiovascular
disease [31, 32]. This reversed social behavior of the epi-
demic of diabetes and cardiovascular disease may impose
an even greater complexity to the health system of these
nations. Another significant issue that merits discussion
is the age at which people develop or die from diabetes
and/or cardiovascular diseases; in the emerging world, in-
dividuals die from these diseases at significantly younger
ages than are observed in developed countries.
Global initiative to halt renal and cardiovascular disease
The International Society of Nephrology held a
groundbreaking conference on the prevention of renal
diseases in the emerging world at the Bellagio Study
and Conference Center of the Rockefeller Foundation
in March of 2004. The participants discussed the recent
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knowledge on the pathogenetic significance of chronic
renal disease and its relationship with vascular injury,
in particular in diabetes mellitus and essential hyperten-
sion. Epidemiologic analyses were presented, revealing
the enormous increases in the burden of these diseases
for developing nations, as well as the mounting worldwide
inequity in the availability of high technology therapies,
such as renal replacement therapy for the millions of pa-
tients needing this treatment option. During the course of
this workshop, it was concluded that if the actual alarming
trend of anticipated increase in the incidence and preva-
lence of chronic conditions continues (in particular, dia-
betes mellitus and its associated complications), financial
as well as human resources will be inadequate to provide
care to individuals suffering these diseases. The urgent
need for early detection and prevention in this area was
extensively discussed in order to promote the establish-
ment of programs directed toward forestalling the global
threat of a pandemic beyond control.
Chronic kidney diseases have become a major health
threat for the entire global community, and again the
steeper increase in their incidence and prevalence is oc-
curring in the emerging nations [2–5]. The main cause of
death of most patients with chronic renal disease (an esti-
mated 50 million globally) is cardiovascular disease. Each
year, over one million individuals develop end-stage re-
nal disease, which requires expensive renal replacement
therapy (dialysis or kidney transplantation), not taking
into consideration that in many countries the majority
of those who reach this stage will never receive therapy.
Type 2 diabetes mellitus is a major contributor to the con-
stant rise in incidence of end-stage renal disease. Other
conditions, such as hypertension and life-style changes
(obesity, sedentarism, smoking, etc.), further increase the
likelihood of vascular injury and, consequently, renal in-
jury. Even with the availability of dialytic treatment, di-
abetic patients face a dismal prognosis because less than
20% of them are alive after five years of initiation of
dialysis. The appearance of renal failure in the diabetic
patient is an indicator of advanced vascular and organ
injury, and is often accompanied by other manifestations
of cardiovascular disease [12].
The implementation of new diagnostic as well as ther-
apeutic strategies to reduce risk factors for the devel-
opment of diabetes and its associated complications in
populations at risk is of utmost importance [14]. In addi-
tion, there is a clear need to establish programs for the
early detection of those patients at risk of developing re-
nal disease, and to prevent further progression. For this to
take place, it is necessary to raise awareness and increase
knowledge of risk factors, as well as preventive measures
in the general public, primary care physicians, as well as
government officials, and policy makers.
Current knowledge of the pathophysiology of type 1
diabetes mellitus has allowed us to determine that the
disease progresses through five distinct stages. Type 2
diabetes follows a similar pattern. This knowledge also
allows us to establish preventive and therapeutic ma-
neuvers to patient populations in accordance with the
stage of progression of the disease itself [12]. Stage I is
mainly characterized by hyperglycemia, hyperfiltration,
and glomerular hypertrophy. Stage II is accompanied
by the emergence of microalbuminuria, which has been
demonstrated to be an early marker of renal disease, with
a strong positive predictive value for the later develop-
ment and progression of renal disease. Stage III is char-
acterized by the development of systemic hypertension
and overt proteinuria, which is usually progressive in na-
ture and heralds a decline in glomerular filtration rate and
subsequent renal insufficiency. Stage IV is accompanied
by progressive renal insufficiency and sustained hyper-
tension, while Stage V denotes the presence of end-stage
renal disease requiring renal replacement therapy.
Microalbuminuria
Microalbuminuria is a well-known risk indicator for
pathologic renal involvement, cardiovascular injury, and
death in diabetic patients [12–17]. Microalbuminuria may
even precede the appearance of type 2 diabetes mellitus,
being present in the insulin resistance syndrome, and it is
associated with conditions such as obesity and hyperten-
sion. In addition, in individuals with essential hyperten-
sion, microalbuminuria constitutes a marker of cardio-
vascular and renal disease. Moreover, microalbuminuria
is emerging as a useful marker to predict cardiovascular
risk in the general population [18]. The precise molecular
mechanisms that link elevated excretion of urinary pro-
teins to cardiovascular and renal disease, and that may
even predict clinical outcomes (morbidity and mortal-
ity) in patients with glucose intolerance or diabetes (and
even in the general population), are still poorly under-
stood. It has been suggested that microalbuminuria may
be a consequence of a state of renal endothelial dysfunc-
tion, low-grade inflammation, and, in general, vascular in-
jury [12]. The presence of microalbuminuria is one of the
earliest clinical markers of renal involvement in diabetic
patients, and it is widely accepted that it precedes the
development of overt albuminuria (>300 mg/day) and
progressive deterioration of renal function to end-stage
renal disease. Primary prevention is directed at normoal-
buminuric patients (Stage I), when regular screening for
microalbuminuria in order to detect its appearance is of
utmost importance, as it is at this point that therapeutic
measures may be of maximal benefit to prevent or at least
delay the development of renal injury [12–17].
Treatment strategies
Establishment of intensive glycemic control has clearly
been demonstrated to reduce urinary albumin excretion
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rates (surrogate end point), and to prevent or retard the
development of chronic diabetic complications, including
diabetic nephropathy leading to end-stage renal disease
(actual end point) [19–20]. Also at this early stage, several
clinical studies have shown that blood pressure–lowering
medications, in particular angiotensin-converting en-
zyme inhibitors (ACEi) or angiotensin II receptor block-
ers (ARBs), may induce a beneficial effect in terms of re-
duction of microalbuminuria and subsequent reduction
of progressive renal injury [21–26].
Diabetic renal disease is almost universally accom-
panied by the development of hypertension, and it has
been known for over 20 years that antihypertensive treat-
ment in these patients delays the progression of renal in-
jury. Hemodynamic and nonhemodynamic mechanisms
are responsible for this beneficial antihypertensive effect.
Knowledge of the pathophysiologic participation of the
renin-angiotensin-aldosterone (RAAS) system in the re-
nal injury of diabetic and other forms of renal disease, and
the subsequent development of pharmacologic interven-
tions to block this system have significantly improved our
ability to treat the diabetic patient with nephropathy. Fur-
thermore, it is clear that the beneficial renoprotective ef-
fect of ACE is and ARBs is at least partially independent
of their antihypertensive effects, and they induce reduc-
tion or regression of microalbuminuria in the early states
of renal injury in the absence of hypertension. Extensive
clinical evidence provided by multicenter, randomized,
double-blind controlled studies supports blockade of the
RAAS as one of the cornerstones of treatment in retard-
ing progression of renal injury in the diabetic population
[21–26]. In addition to the discussed preventive strategies
at this primary stage, we have to stress the importance of
lifestyle habits (smoking cessation, increase in physical
activity, and reduction of obesity), which may be useful
at any point in the development of the diseases, and yet
may have their greatest impact at this stage.
Secondary prevention is directed to establish “early
treatment interventions” to diabetic patients who have
already developed microalbuminuria and are at risk of
progressing to overt diabetic nephropathy and eventually
to end-stage renal disease. At this stage, microalbumin-
uria is also clearly important to monitor progression, as
well as the therapeutic response to treatment of diverse
natures, including intensive glucose control and, partic-
ularly, the antiproteinuric effect of ACEi or ARBs. Ter-
tiary care is directed to providing life-supporting medical
procedures, including transplantation and dialysis, and is
accompanied by complex morbid complications and, as
commented before, extremely high costs. The progres-
sion of fewer patients to this tertiary care stage should be
the major goal in establishing intensive primary and sec-
ondary prevention programs. It is nonetheless important
to point out that many patients do not reach end-stage
renal disease because they develop other cardiovascular
complications and even death, all of which may bene-
fit from the primary and secondary preventive measures
described before.
Screening and treatment in the developing countries
The presence of microalbuminuria as an early marker
of renal dysfunction calls for its extended use as a mon-
itoring tool to provide an indication of the stage of the
disease [14–18, 27]. Screening for small amounts of uri-
nary albumin leakage allows for the early identification of
patients who can benefit from the renal protective effects
of blockade of the RAAS system. Given the extremely
high costs of treatment of end-stage renal disease, as well
as other cardiovascular complications, it is clear that this
procedure may be highly cost-effective and an invaluable
aid to mitigate the very large financial burden of treating
end-stage renal disease, and may also favor better patient
outcomes in the developing world [28–30]. We believe
that this approach may be the one to offer a future in
terms of control of an epidemic of diabetes mellitus, dia-
betic nephropathy, and other chronic vascular diseases.
From the previous discussion we believe it is clear that
there is an urgent need for the specific formulation and
implementation of programs and strategies directed to-
ward primary and secondary prevention of diabetes mel-
litus and its complications, as well as the establishment of
preventive measures directed to reduce the emergence of
other chronic vascular diseases. In this context, chronic
renal failure has been recognized as a major health threat
for the whole world community and, in particular, for
emerging nations. Development and implementation of
successful strategies will necessarily imply joint efforts
that should include national governments, international
agencies, physicians and other health workers, pharma-
ceutical industry, insurance companies, patients, and their
relatives. Primary prevention usually faces difficulties for
accessing adequate funding from government sources;
given known financial constraints, and in addition to diffi-
culties in selling the programs as cost-effective strategies
in the short term, a timeframe which may be unreward-
ing in political terms. It may therefore be necessary to
gain support from public, industry, and other players, as
well as to translate gains projected into financial gains,
in order to generate a clear message that can be better
understood and justified for public funding.
Effective programs are required in the first instance in
order to raise awareness and to educate the general pub-
lic, patients, as well as policymakers, to generate changes
in lifestyle that may by themselves reduce the risk of
development of chronic conditions (tobacco consump-
tion, sedentarism, excessive carbohydrate and fat in di-
ets, etc.). Companies in part responsible for these in-
creased risk factors should be made accountable and co-
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participant in the funding required to develop massive
educational campaigns. Parallel to the previous effort,
we require effective, simple, and inexpensive programs
directed toward early detection of cardiovascular risk.
Blood glucose, systemic blood pressure, and microalbu-
minuria measurements play a key role in these programs.
Microalbuminuria may be of particular importance given
its power as a marker for the development of progressive
renal injury as well as cardiovascular disease.
Once early stages of renal and/or cardiovascular dis-
eases are detected, again, simple procedures directed to
prevent further progression need to be put in place. At
early stages, emphasis will have to be shared between
lifestyle changes (reduction in sodium intake and other
dietary indications in diabetics), as well as early pharma-
cologic interventions that should include RAAS block-
ade either with an ACEi or with an ARB, and possibly
with other drugs, such as daily low-dose aspirin or statins,
if hyperlipidemia is present [33]. The pharmaceutical in-
dustry may actively participate at this stage and could pro-
vide significant support in developing nations as a mark of
social responsibility, given the significant profit obtained
by the therapies referred to. Extensive preventive pro-
grams can provide the tools to reduce very significantly
the costs of therapeutic measures, such as the referred
medications, as well as diagnostic tools such as office dip-
stick microalbumin detection.
In addition to what has been stated in the previous
paragraph, other useful tools for emerging nations are
the development or adaptation of existing diagnostic and
therapeutic guidelines [27]; in conjunction with these ini-
tiatives, there is a clear need for reliable registries because
those in place where they do exist are often unreliable.
The process of building the required infrastructure and
programs has to be well planned from the inside of each
society with global assistance when possible, always tak-
ing in account its special needs and characteristics. All the
educational processes have to be tailored according to the
needs of the local institutions, and regional needs, taking
into account local or international experiences, yet not
necessarily miming other programs developed in other
latitudes. Doing it this way may provide a better oppor-
tunity for retention of health workers and physicians in
the programs and for a greater success of the programs
themselves.
Finally, there is a clear need to develop and extend local
clinical and epidemiologic research programs in develop-
ing countries which will result in acquisition of knowledge
required to succeed in implementing preventive medicine
programs. Action for control of chronic diseases, in par-
ticular, diabetes mellitus and other cardiovascular con-
ditions, requires immediate attention that cannot be de-
layed by long-term cohort studies or interventional trials
that could prove to be extremely costly for emerging na-
tions. An adequate policy would imply the initiation of
extensive educational and control strategies, extrapolat-
ing knowledge previously obtained elsewhere with the
simultaneous development of local population and risk
factor studies that may allow us to better understand and
control local conditions.
It is important to point out that the epidemiologic tran-
sition was previously viewed as a one-way road, starting
with the predominance of infectious diseases as causes of
death and transition to the advent of noncommunicable
diseases being responsible for losses of lives. Health and
disease is a complex and constantly evolving dynamic pro-
cess, and that where a certain disease disappears, others
may re-emerge.
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